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Abstract
Background: Whiplash-associated disorders (WAD) are an enormous and costly burden to Australian society. Up to
50% of people who experience a whiplash injury will never fully recover. Whiplash is resistant to treatment and no
early management approach has yet been shown to prevent chronic pain. The early presence of central
sensitization is associated with poor recovery. Pregabalin’s effects on central sensitization indicate the potential to
prevent or modulate these processes after whiplash injury and to improve health outcomes, but this has not been
investigated. This paper describes the protocol for a feasibility study for a randomised controlled trial of pregabalin
plus evidence-based advice compared to placebo plus evidence-based advice for individuals with acute whiplash
injury who are at risk of poor recovery.
Methods: This double blind, placebo-controlled randomised feasibility study will examine the feasibility and
potential effectiveness of pregabalin and evidence-based advice (intervention) compared to placebo and evidence-
based advice (control) for individuals with acute whiplash injury at risk of poor recovery. Thirty participants (15 per
group) aged 18–65 years with Grade II WAD, within 48 hours of injury and currently experiencing at least moderate
pain (NRS: ≥ 5/10) will be recruited from Emergency Departments of public hospitals in Queensland, Australia.
Pregabalin will be commenced at 75 mg bd and titrated up to 300 mg bd as tolerated for 4 weeks followed by
1 week of weaning.
Results: The feasibility of trial procedures will be tested, as well as the potential effect of the intervention on the
outcomes. The primary outcome of neck pain intensity at 3 months from randomisation will be compared between
the treatment groups using standard analysis of variance techniques.
Discussion: Feasibility and potential effectiveness data will inform an appropriately powered full trial, which if
successful, will provide an effective and cost-effective intervention for a costly and treatment resistant condition. It
will also have implications for the early management of other traumatic conditions beyond whiplash.
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Background
In the majority of Western countries, whiplash is the
most frequent injury resulting from a motor vehicle
crash (MVC) [1]. MVCs result in 50 million injuries
worldwide and nearly four million emergency depart-
ment (ED) consultations in the US per year [2]. In
Australia, non-hospitalised minor injuries such as whip-
lash comprise about 72% of all survivable MVC injuries
[3], with total annual costs of over $950 million [3]. The
cumulative incidence of whiplash injuries resulting from
MVCs has increased to over 300/100,000 people in
North America and Western Europe since 1990 [4].
Up to 50% of people with whiplash injury will never
fully recover [5] and up to 30% will remain moderately
to severely disabled [5]. Most recovery, if it occurs, takes
place in the first 2–3 months, after which time recovery
plateaus [6, 7]. This indicates that early treatment will be
crucial for better recovery; yet, existing early treatment
approaches are inadequate. Although current clinical
guidelines recommend exercise and maintaining activity
for acute whiplash [8], several systematic reviews con-
clude that exercise/activity-based interventions provide
only small effects [9–11]. Early multidisciplinary man-
agement (mainly physiotherapy and psychology) is also
no more effective than usual care [12]. Behavioural inter-
ventions, such as education and advice, also demonstrate
only small effects [10]. The effectiveness of medication
in the early treatment of whiplash has been flagged as an
urgent research need for several years [13], including at
the International Summit on Whiplash Injury in 2011
[14]. Our analysis of data from the multi-year Bettering
the Evaluation and Care of Health (BEACH) study of
General Practitioner (GP) activity in Australia found that
medications are prescribed for most whiplash cases [15],
yet a recent review found no studies to support the ef-
fectiveness of any medication for whiplash-associated
disorders (WAD) [16].
The most consistent predictor of poor recovery is
higher initial levels of pain [17]. The early presence of
pro-nociceptive mechanisms (widespread hyperalgesia,
allodynia and spinal cord hyperexcitability (via nocicep-
tive withdrawal reflexes) that does not accommodate
within a few weeks) are also associated with poor recov-
ery [18]. Some studies indicate that patients with these
pro-nociceptive features do not respond as favourably to
physical rehabilitation as those without these features
[19]. Addressing initial pro-nociceptive mechanisms in
the early acute post injury stage may improve long-term
outcomes for this patient group.
Pregabalin is an obvious medication choice for this
purpose. It acts to reduce central sensitization and, if
shown to be effective, would alleviate concerns about
prescription opioids by reducing the incidence of
chronic pain, and therefore the need for long-term opi-
oid use. The use of opioids in this patient group is a
concern; indeed, the misuse of prescription opioids in
the US and Canada has been described as a public health
crisis, with evidence that a similar problem is developing
in Australia [20]. Our research has shown that 39% of
prescribed medications for WAD in general practice
were opioids [15], with US data showing that early
provision of opioids in the hospital ED for MVC injury
patients is associated with continued use 6 weeks later
[21]. Both findings highlight a potential risk for opioid
misuse in this patient group.
Pregabalin, an anti-epileptic drug, reduces excitability
of dorsal horn neurons after tissue damage, blocking de-
velopment of pronociceptive mechanisms. It is a struc-
tural analogue of the inhibitory neurotransmitter g-
aminobutyric acid, binding to the voltage-gated calcium
channels, reducing the release of several excitatory neu-
rotransmitters, and blocking the development of hyper-
algesia and central sensitization [22]. Pregabalin is
effective for chronic neuropathic pain conditions such as
postherpetic neuralgia and painful diabetic neuropathy
[23] and fibromyalgia, which has similar underlying pain
processes to WAD [23]. However, treatment with prega-
balin did not significantly reduce leg pain intensity or
improve other outcomes in patients with mainly chronic
sciatica, compared with placebo [24]. More importantly
for our trial, pregabalin has been shown to prevent the
development of chronic pain following acute injury, in
the form of surgery. Buvanendran et al. [25] showed that
administering pregabalin perioperatively and for 2 weeks
postoperatively reduced the incidence of chronic neuro-
pathic pain at 3 and 6 months after total knee arthro-
plasty, with less opioid consumption and better range of
motion during the first 30 days of rehabilitation. Simi-
larly, less pain and improved functional outcomes have
been shown for pregabalin following spinal surgery [26,
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27]. Recent systematic reviews concluded that use of
pregabalin yields reductions in chronic postsurgical pain,
is more effective in surgical models associated with pro-
nociceptive mechanisms [28], and shows promise in pre-
venting the transition from acute to chronic pain [29,
30]. Notably, pregabalin has positive effects on anxiety
[31], indicating the potential to ameliorate symptoms of
stress and arousal common after whiplash injury [32].
While surgery differs from the pain due to musculo-
skeletal injury in many ways, the pro-nociceptive mecha-
nisms involved remain the same. Yet, despite this
commonality, no studies have investigated effects of
pregabalin following injury or trauma. Given the promis-
ing results in surgical populations, there is sufficient evi-
dence to support the hypothesis that pregabalin used in
acute whiplash injury may prevent or modulate pro-
nociceptive mechanisms and improve health outcomes
for this treatment-resistant condition. In light of this, we
propose to test the feasibility of conducting a clinical
trial of pregabalin for individuals with acute whiplash in-
jury at risk of developing chronic pain.
Initially, we will conduct a feasibility study to hone eli-
gibility criteria, test recruitment strategies, and develop a
model for recruitment for the subsequent full scale trial,
which is endorsed by the Australian and New Zealand
Musculoskeletal Clinical Trials Network.
Specific objectives
1. To evaluate feasibility by estimating expected rates
of:
i. Recruitment (number of patients approached,
number consenting to participate, and number
eligible to be randomised)
ii. Missing data and participant attrition
2. To test recruitment strategies and develop a model
for recruitment to a full trial
3. To identify relevant factors that could create barriers
to subsequent study completion, and develop
strategies to overcome these
4. To assess the potential effectiveness of pregabalin in
reducing pain for patients with acute WAD at risk of
poor recovery to determine the adequate sample size
for a definitive full-scale effectiveness randomised
controlled trial (RCT)
5. To obtain feedback from ED clinicians, local General
Practitioners (GPs), trial GPs and patients on their
experience with the trial and areas for improvement
to inform a full-scale trial
The study will not attempt to provide evidence of clin-
ical effectiveness for pregabalin in people with acute
WAD. This is in accordance with the recommendations
from the National Institute of Healthcare Research
(NIHR) guidelines [33] and the Consolidated Standards
of Reporting Trials (CONSORT) for the development of
pilot and feasibility studies [34].
Methods/design
Design overview
This is a double-blind, randomised, controlled feasibility
study, with 30 voluntary participants (15 per group) with
acute whiplash (symptoms < 48 hours) randomly allo-
cated to receive either pregabalin and evidence-based
advice, or placebo and evidence-based advice in a 1:1 ra-
tio, for 4 weeks followed by 6 days of weaning. Out-
comes will be measured at baseline, 5 weeks, and 3, 6
and 12 months post-randomisation. Study flow is illus-
trated in Fig. 1.
The protocol is reported according to the Standard
Protocol Items: recommendations for randomized con-
trolled trials (Fig. 3 SPIRIT diagram and Additional file
1: SPIRIT checklist).
Fig. 1 Flow chart of study design
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Setting
Public hospitals in Queensland, Australia (Gold Coast
University Hospital (GCUH) and Ipswich Hospital), and
nearby General Practice clinics.
Participants
Inclusion criteria
 Individuals with Grade II WAD and within 48 hours
of injury
 Currently experiencing at least moderate pain (visual
analogue scale: ≥ 5/10)
 Aged 18–65 years
 Proficient in written and spoken English
Exclusion criteria
 Known or suspected serious spinal pathology (e.g.
metastatic disease of spine)
 Confirmed fracture or dislocation at time of injury
(WAD IV)
 WAD III (neurological compromise, e.g. decreased
reflexes, muscle power)
 Previous whiplash injury or neck pain condition
requiring treatment
 Patients using gabapentin/pregabalin
 Patients with known peripheral neuropathy
 Known hypersensitivity to pregabalin use (hives,
blisters, rash, dyspnea and wheezing)
 History of renal insufficiency
 Women who are pregnant or breastfeeding
 History of psychiatric illness or substance abuse
 Patient Health Questionnaire (PHQ-2) of 3 or more
[35]
 Inability to speak and write in English
Recruitment and procedure
Recruitment will be from EDs of public hospitals in
Queensland, Australia. Research staff will regularly
check the Emergency Department Information System
(EDIS) and identify any potentially eligible patients. They
will liaise with an ED doctor to ensure the patient’s his-
tory and screening results are clear for study commence-
ment. Eligible participants who present at ED when
research staff are present will complete informed con-
sent documentation after discussion with the ED doctor,
fill out baseline measures, including expectations of re-
covery, and then be randomly allocated to pregabalin
plus evidence-based advice or placebo plus evidence-
based advice.
If participants present at times when no research staff
are in attendance, they will be asked by an ED doctor or
nurse to provide written consent for the research team
to contact them as soon as is practicable. If, when
contacted, these patients agree to be involved in the trial,
they will be screened at a local GP clinic, provide in-
formed consent after discussion with the GP, and then
be randomised and provided with the first medication
dose.
After discharge from ED, the trial GP will evaluate all
patients via telephone review (3 days after randomisation
and then weekly thereafter) to titrate the dose based on
the patient’s tolerance and any adverse effects, and to
promote retention. Participants will be offered an op-
tional GP visit during the active intervention phase. Par-
ticipants will also be able to contact the trial GP if they
have questions regarding the medication dose or any
side effects.
Strategies for reaching target sample size include
employing casual staff to monitor EDIS for as much of
the 24 hour day as possible, using a permission to con-
tact process for patients arriving in ED when there are
no research staff, regularly reminding ED nurses and cli-
nicians about the trial, and maintaining a high profile of
the trial in the ED.
Randomisation
Participants will be randomly allocated to either treat-
ment group. The randomisation codes will be generated
by the study statistician using computer-generated ran-
dom numbers. The statistician will provide a randomisa-
tion list in variable block sizes of 4–6 for the whole trial
to the study dispensing pharmacy, unavailable to those
who enrol participants. To balance potential con-
founders and to conceal allocation, there will be separate
randomisation schedules for each site. The randomisa-
tion schedule, containing patient initials, date of birth
and randomisation code, will be kept in a sealed enve-
lope in a locked filing cabinet in the pharmacy, and will
be accessible after hours in case unblinding is needed.
Study medication will be prepared according to the ran-
domisation schedule by a pharmacist not involved with
data collection, then sealed in an opaque medication kit
and stored in a locked drug room in the ED or at the Gen-
eral Practice. Allocation will occur immediately following
baseline assessment. The doctor or nurse (blinded) will se-
lect the next kit in the box, record the participant’s ran-
domisation number and provide the sealed medication kit
to the participant (blinded). This will randomise them to
one of two groups – pregabalin or placebo – and ensure
concealed allocation and blinding of research staff, trial
GPs, participants, care providers, outcome assessors and
data analysts. Participants will be considered to have en-
tered the study when the kit is opened.
Study interventions
Using placebo as a comparator will allow us to compare
pregabalin plus evidence-based advice with evidence-
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based advice only. All patients will receive a self-help re-
source to aid recovery (evidence-based advice), which
describes the most effective interventions currently
available (reassurance and an active physical regime in-
cluding exercises) [36], ensuring no patient is without
any treatment.
Evidence-based advice
On randomisation, an evidence-based advice booklet
Whiplash Injury Recovery: A Self Help Guide (2ndedition)
[36], based on recommendations of the current Austra-
lian Guidelines for Whiplash Management, will be given
to all patients. It provides information about whiplash,
assurance about prognosis, advice to stay active and re-
sume working, information on correct posture and re-
suming functional daily activities and an exercise
program proven to reduce neck pain.
Pregabalin or placebo
Pregabalin and placebo identical in size, appearance,
smell, taste and weight (Avicel®) will be encapsulated by
a compounding pharmacy to ensure blinding of research
staff, participants, ED staff and trial GPs.
Dose titration Patients will receive one pregabalin cap-
sule (75 mg) or one placebo capsule orally twice daily
starting immediately on randomisation. Figure 2
delineates the dose escalation/reduction/modification
regimen, which is standard clinical practice, and has also
been used in previous pregabalin trials [37, 38].
Rationale for duration of treatment There are no firm
guidelines on treatment duration. Surgical studies have
used pregabalin for 10 days to 2 weeks post-operatively
[30]. For chronic neuropathic pain, 2–4 weeks of treat-
ment is recommended [39]. In a recent trial, patients
with sciatica were treated for up to 8 weeks [25]. To
avoid missing benefit we will give 28 days of treatment
before weaning.
Concomitant medications
Participants will be asked not to seek other treatments
and where possible not to change current medications,
and GPs will be asked within reason to refrain from re-
ferring or suggesting additional or alternative treatments.
All participants will maintain diaries in which they will
record information about other treatments and medica-
tion taken. During the trial, GP’s calls to patients, all
medications and doses will be recorded, including pre-
scription and over-the-counter medications and natural
health products, to be included in the analysis. At the
end of 5 weeks, participants will be permitted to seek
further treatment (e.g. additional medication,
Fig. 2 Dosing algorithm for pregabalin/placebo
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physiotherapy, etc.) if required, information about which
will be recorded in cost diaries during follow-up.
Breakthrough medication
Participants who experience high levels of continuing or
worsening pain will be able to return for review by the
trial GP. If there is debilitating continuing and worsen-
ing pain or continuing high levels of pain that have not
improved after 7 days of treatment, despite following the
trial regimen, rescue medication (Paracetamol 1000 mg
qid prn or oxycodone 5 mg prn if paracetamol is not
sufficient) will be provided by the trial GP. These medi-
cations are consistent with current clinical practice
guidelines for WAD management [8]. Ancillary and
post-trial care will be provided by the patient’s GP.
Adherence to study medication
Adherence will be assessed by (1) daily self-recorded
medication intake, (2) counts of returned tablets follow-
ing treatment completion and (3) the trial GP will ask
about adherence during telephone-based reviews starting
at 3 days post randomisation. Adherence will be encour-
aged during weekly phone calls to participants. There
will be full accountability for all drugs given to patients.
Study outcome measures
Primary outcome
1. Average neck pain intensity over the last 24 hours at
3 months post randomisation measured using the
Numeric Pain Rating Scale (NRS) [40] of 0–10.
Secondary outcomes: feasibility
1. Proportion of screened patients eligible
2. Proportion of eligible patients enrolled
3. Enrolment rate (i.e. number of enrolments per
month per site)
4. Protocol compliance
5. Logistic model for recruitment to a full trial,
including staffing requirements, and strategies to
overcome any barriers identified, for example,
recruiting through GP practices using the
‘permission to contact’ system for patients who have
presented to ED, if recruitment is easier than
through EDs directly
6. Feedback from ED clinicians, local GPs, trial GPs
and patients on their experience with the trial and
areas for improvement, to inform a full scale trial
Secondary outcomes: clinical
1. Neck pain intensity (NRS 24 hours) at 5-week and
6- and 12-month follow-ups post randomisation
2. Neck Disability Index (NDI) [41] at 5 weeks, 3, 6
and 12 months to measure disability
3. Pain Catastrophising Scale (PCS) [42] at 5 weeks, 3,
6 and 12 months to measure pain catastrophising
4. Post-traumatic Stress Diagnostic Scale (PDS)
symptom score [43] at 5 weeks, 3, 6 and 12 months
to measure post-traumatic stress symptoms
5. Depression, Anxiety and Stress Scale (DASS) [44] at
5 weeks, 3, 6 and 12 months
6. Generic measure of health status scores (SF-12) [45]
at 5 weeks, 3, 6 and 12 months
7. Proportion of patients who lodge a compensation
claim at 5 weeks, 3, 6 and 12 months
8. Number of doses of breakthrough medication taken
measured at 5 weeks, 3, 6 and 12 months
9. Number of adverse events compared between
treatment groups
10.S-LANSS [46] during follow-up from baseline, com-
pared between treatment groups
Outcome measures have established reliability and val-
idity, are recommended by the International Whiplash
Summit [14] and the Bone and Joint Decade Neck Pain
Task Force [47], and follow IMMPACT recommenda-
tions for design of clinical trials for chronic pain preven-
tion [48].
The Recommendations for Interventional Trials
(SPIRIT) figure demonstrates the timing of the interven-
tions and outcomes (Fig. 3).
Sample size
Since this is a feasibility study, a sample size calculation
was not performed. We will aim for 30 participants (15
in each arm) as this will be a large enough sample to in-
form about the practicalities of delivering the interven-
tion in the ED, recruitment, uptake and attrition. The
results of this study will inform any necessary post-trial
modifications or remodelling prior to implementation of
a larger scale multisite RCT.
Loss to follow-up
This feasibility study aims to assess attrition rates for a fu-
ture large RCT. In order to reduce attrition, we will aim to
foster trusting relationships via weekly telephone calls to
help participants feel engaged in the study. This will also
improve adherence to intervention protocols. If partici-
pants discontinue or deviate from intervention protocols,
we will attempt to collect at least the primary outcome.
Unblinding
The Principal Investigator will be able to unblind indi-
vidual cases if any of the following criteria are met:
1. Emergency unblinding – to make a clinical
treatment decision or when an unexpected serious
adverse event occurs
2. At the request of the Data Safety Monitoring Board
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3. At the conclusion of the study to determine the
potential effect of intervention
If a medically qualified investigator requires identifica-
tion of the trial medication composition, they must
quote the randomisation code, participant initials and
date of birth to the Principal Investigator, who will con-
tact the pharmacy and quote the randomisation code
and trial title. The pharmacy will unblind for the specific
participant only. The medically qualified investigator will
talk to and unblind the participant.
Data management
This trial will be conducted in accordance with ICH Guide-
lines for Good Clinical Research Practice [49] and relevant
local ethical regulations. Study data will be collected and
managed using a regulatory approved electronic data cap-
ture system (REDCap) hosted at UQ [50], on the UQ server.
REDCap is a secure, web-based application designed to sup-
port data capture for research studies, that will house all
clinical and safety data. It will provide (1) an intuitive
interface for validated data entry; (2) audit trails for tracking
data manipulation and export procedures; (3) automated ex-
port procedures for seamless data downloads to common
statistical packages; and (4) procedures for importing data
from external sources.
Data from follow-up questionnaires will be entered by pa-
tients via email links to the REDCap database, and the
remaining data by the research team. Data quality will be
assured through range checks for data values. Integrity of
trial data will be monitored by regularly scrutinising data
for omissions and errors. In order to protect confidentiality
before, during and after the trial, personal information
about potential and enrolled participants will remain secure
in a locked research office at GCUH or Ipswich Hospital.
Study data will be retained, securely password protected,
for a minimum of 15 years from completion. Details of data
management procedures can be found in the protocol.
Data analyses
Because of participant numbers and the aims of the
study, we will report descriptive analyses. Recruitment
Fig. 3 SPIRIT diagram
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rate (number of patients approached, number consent-
ing to participate and number eligible to be randomised)
will be reported, as will frequencies and proportions of
missing data and participant attrition, both during inter-
vention and follow-up periods.
A model for recruitment to the main trial will be de-
scribed, including the success of various recruitment strat-
egies, for example, is recruitment easier though EDs or
through GP practices using the ‘permission to contact’ sys-
tem? It will also include how the ED and general practice
sites worked together, how to maximise research staffing
efficiency in terms of rostering, etc. Relevant factors that
could create barriers to subsequent study completion will
be described, and strategies to overcome these discussed.
Statistical analysis
Trends in the data will be analysed by our biostatistician
blinded to group allocation using intention-to-treat. We
will analyse the effect of treatment separately for each
outcome using mixed-effects models with random inter-
cepts for individuals to account for correlation of re-
peated measures within participants. Treatment group
will be included as a fixed effect. We will obtain esti-
mates of the effect of the intervention and 95% confi-
dence intervals by constructing linear contrasts to
compare the adjusted mean change (continuous vari-
ables) or difference in proportions (dichotomous vari-
ables) in outcome from baseline to each time point
between the pregabalin plus evidence-based advice and
placebo plus evidence-based advice groups. Missing data
will be examined for patterns of missingness.
Secondary outcomes
Because of participant numbers, we will present descrip-
tive analyses of the secondary outcomes.
Cost related data and analyses
Cost diaries, a reliable and valid tool for determining
costs in cost-effectiveness research [51], will be collected
at each follow-up assessment. In this study we will test
the feasibility of using these diaries.
Direct costs (e.g. general practitioner, physiotherapy,
chiropractor, pharmaceutical services) will be calculated
using market prices estimated from Medicare Benefits
Schedule, worker’s compensation scheme payment
schedules and Pharmaceutical Benefits Scheme. Direct
healthcare costs (e.g. consumer co-payments) and non-
healthcare costs not captured by insurer payments, will
be identified. Examples include other professional care,
transportation costs and time spent by family members
or volunteers providing care.
Indirect costs include lost economic productivity due
to the injury. A shadow wage rate will be used to identify
opportunity costs of time spent away from work,
calculated using income and employment data collected
at baseline. Utility weights will be generated using par-
ticipants’ SF-12 responses, translated to SF-6D utilities
[52] using a new Australian algorithm [53]. The resulting
cost-effectiveness measure will be cost per QALY saved.
N-way sensitivity analyses will model second-order un-
certainty (e.g. magnitudes of probabilities, treatment ef-
fects) where appropriate.
Monitoring
Collecting, assessing, reporting and managing adverse
events
The most common side effects of pregabalin are dizzi-
ness and sedation; the dose will be titrated as tolerated.
Leg oedema can also develop and may require discon-
tinuation. More severe side-effects are rare.
Information about solicited and spontaneously re-
ported adverse events will be sought from all partici-
pants during telephone reviews by the trial GP. If a
participant reports an adverse event, the trial GP will de-
termine appropriate action, which may include dose al-
teration or withdrawal. If a serious adverse event (SAE)
is identified, the trial GP will forward this information
immediately to the Principal Investigator and Data
Safety Monitoring Board. All SAEs, suspected adverse
reactions and serious unexpected suspected adverse re-
actions will be recorded immediately in the source docu-
ments, and on the adverse event case report form. Each
event will be followed until resolution, stabilisation or
until it has been determined that the study treatment is
not causal. SAEs still ongoing at the end of the study will
be followed up to determine final outcome. Any SAE oc-
curring after the study considered to be possibly related
to study treatment will be recorded and reported imme-
diately. Compensation to those who suffer harm from
trial participation will be provided by the trial sponsor.
Withdrawals
Participants will be withdrawn if they develop any exclu-
sion criteria or if they choose to do so, without prejudice
to current or future management. The follow-up schedule
will continue unchanged for all randomised participants
unless a participant chooses to withdraw from follow-ups.
If participants cannot complete follow-up outcome mea-
sures online or on paper, or are lost-to-follow-up and/or
are non-compliant with dosing, we will employ phone
calls, home visits and/or communication with their GP.
Patients who withdraw during dosing will be made aware
of the need for weaning from study medication.
Dissemination
Authorship eligibility guidelines will follow ICMJE
guidelines. The final trial dataset will be available to the
investigative team and on reasonable request.
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Discussion
Chronic pain and disability following whiplash injuries is
an enormous health and economic burden for Australia
and other industrialised countries. Current treatments
offer only modest benefit. This feasibility study will as-
sess the feasibility and potential effectiveness of an in-
novative early intervention delivered to ‘high-risk’
individuals in EDs. Feasibility and potential effectiveness
data will inform a full trial, which if successful, will pro-
vide an effective and cost-effective intervention with im-
mediate clinical applicability for a costly and treatment
resistant condition. It will also have implications for
early management of other traumatic conditions.
The protocol was developed for an ‘at risk’ population
by a team including a physiotherapist, pain specialist,
ED clinician researcher, GP, clinical psychologist and
biostatistician.
The primary effectiveness measure is neck pain inten-
sity at 3 months from randomisation for this feasibility
study. Measuring this at 3, 6 and 12 months will allow
assessment of any sustained effect on outcomes. In the
feasibility trial described here, the study will not be pow-
ered to assess these potential effects, but will allow ne-
cessary post-trial modifications that will maximise
effectiveness of the trial to be implemented prior to the
rollout of a larger scale multisite RCT.
Strengths
This study has been designed and is being conducted in
accordance with the principles of the Declaration of
Helsinki (1996), Good Clinical Practice and all applicable
regulatory requirements. This will increase validity, par-
ticipant safety and scientific integrity as well as reduce
bias. The Trial Steering Committee, which includes key
study investigators, will ensure that study quality is
maintained throughout.
Limitations
Recruiting through EDs means that our cohort of pa-
tients will not be entirely representative of the entire
population of whiplash patients. However, by recruiting
participants through EDs, we will be most likely to enrol
participants with greater pain and distress and therefore
at higher risk of poor recovery – the very group we aim
to target. Data from our current trials [54] would sup-
port this, where patients with acute injury recruited
from ED reported average higher pain levels (6.2 ± 1.5)
compared to those recruited from primary care and ad-
vertisement (4.5 ± 1.0). In addition, we aim to reduce
central sensitization beginning in the early aftermath of
injury, and ED recruitment allows us to recruit patients
within hours of MVC.
Trial status
Protocol version 8 is dated July 2017. Recruitment began
on 20 January 2017 and is ongoing. Important protocol
modifications (e.g. changes to eligibility criteria, out-
comes, analyses) will be communicated to relevant
parties (e.g. investigators, Human Research Ethics
Committees, trial participants, trial registries, journals,
regulators) as needed.
Additional file
Additional file 1: SPIRIT checklist. (DOC 120 kb)
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